Small Business Innovation Research · Small Business Technology Transfer
Celdara Medical, LLC: SBIR & STTR awards
52 awards worth $49.30M to 1 companies since 2009 match these filters. Phase I tests an idea (usually a few hundred thousand dollars); Phase II builds it (often $1M or more).
Celdara Medical, LLC's federal contracts and grants · All SBIR & STTR awards
Awards by year
| Year | Phase I | Phase II | Amount |
|---|---|---|---|
| 2025 | 0 | 1 | $1.23M |
| 2024 | 0 | 1 | $1.84M |
| 2023 | 2 | 3 | $8.07M |
| 2022 | 4 | 1 | $2.72M |
| 2021 | 2 | 0 | $864.7K |
| 2020 | 3 | 2 | $5.83M |
| 2019 | 4 | 2 | $6.36M |
| 2018 | 3 | 1 | $2.98M |
| 2017 | 3 | 2 | $4.75M |
| 2015 | 2 | 2 | $3.50M |
| 2014 | 4 | 1 | $2.62M |
| 2013 | 1 | 0 | $288.3K |
The latest year fills in over months: agencies report awards to SBIR.gov with a lag.
Latest matching awards
| Award | Company | Agency | Phase | Amount | Date |
|---|---|---|---|---|---|
| Development of CM-HZ01 as a non-alpha-IL2 therapeutic for the treatment of metastatic melanoma · topic 102 | Celdara Medical, LLC · New Hampshire | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $1.23M | 2025-01-01 |
| Development of CM-CS1 CAR Treg to Treat Amyotrophic Lateral Sclerosis (ALS) · topic 105 | Celdara Medical, LLC · New Hampshire | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $1.84M | 2024-09-01 |
| Kv2.1-Targeted First in Class Neuroprotective Therapeutic for Acute Ischemic Stroke · topic 105 | Celdara Medical, LLC · New Hampshire | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $653.1K | 2023-09-20 |
| Development of CM-CS1 CAR Treg to Treat Amyotrophic Lateral Sclerosis (ALS) · topic 105 | Celdara Medical, LLC · New Hampshire | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $466.9K | 2023-09-19 |
| Anti-hIAPP for the preservation of pancreatic function in Type 2 Diabetes · topic 200 | Celdara Medical, LLC · New Hampshire | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $2.00M | 2023-09-08 |
| Development of CM-IAV1 for Treatment of High-risk Pandemic Influenzas · topic NIAID | Celdara Medical, LLC · New Hampshire | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $2.00M | 2023-06-12 |
| A human monoclonal antibody therapy for treatment of hantavirus cardiopulmonary syndrome · topic NIAID | Celdara Medical, LLC · New Hampshire | Department of Health and Human Services · National Institutes of Health | STTR Phase II | $2.95M | 2023-03-01 |
| Anti-hIAPP for the preservation of pancreatic function in Type 2 Diabetes · topic 200 | Celdara Medical, LLC · New Hampshire | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $267.8K | 2022-09-22 |
| Preclinical development of CM-CX1 for the treatment of ovarian clear cell and renal cell carcinomas · topic 102 | Celdara Medical, LLC · New Hampshire | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $1.48M | 2022-09-01 |
| Development of a broad spectrum antimicrobial to combat chronic lung infection · topic NHLBI | Celdara Medical, LLC · New Hampshire | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $300.6K | 2022-08-10 |
| CAR T platform to treat solid tumors · topic 102 | Celdara Medical, LLC · New Hampshire | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $368.1K | 2022-08-01 |
| Development of CM-IAV1 for Treatment of High-risk Pandemic Influenzas · topic NIAID | Celdara Medical, LLC · New Hampshire | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $300.0K | 2022-04-25 |
| Preclinical development of CM-CX1 for the treatment of ovarian clear cell and renal cell carcinomas · topic 102 | Celdara Medical, LLC · New Hampshire | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $274.1K | 2021-09-08 |
| A Novel Broad-spectrum Antiviral Agent · topic NIAID | Celdara Medical, LLC · New Hampshire | Department of Health and Human Services · National Institutes of Health | STTR Phase I | $590.7K | 2021-01-01 |
| Biomarker of IAPP dysfunction in prediabetes and early type 2 diabetes mellitus (T2DM) · topic 200 | Celdara Medical, LLC · New Hampshire | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $299.2K | 2020-09-11 |
| Mitigation of Acute Kidney Injury (AKI) using the polymer prodrug, APP-103TM · topic 400 | Celdara Medical, LLC · New Hampshire | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $1.75M | 2020-08-01 |
| Autonomous RNA-Mediated Anti-Influenza A Virus Therapeutics (AMRed Therapeutics) · topic NIAID | Celdara Medical, LLC · New Hampshire | Department of Health and Human Services · National Institutes of Health | STTR Phase I | $258.4K | 2020-04-17 |
| Development of CM-SV1, a monoclonal antibody treatment for Sudan Virus · topic NIAID | Celdara Medical, LLC · New Hampshire | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $2.92M | 2020-03-25 |
| SBIR TOPIC 081: ADJUVANT DEVELOPMENT FOR VACCINES AGAINST INFECTIOUS OR IMMUNE-MEDIATED DISEASES · topic 81 | Celdara Medical, LLC · New Hampshire | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $600.0K | 2020 |
| Antimicrobial peptides to combat MDR ESKAPE pathogens · topic R | Celdara Medical, LLC · New Hampshire | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $298.7K | 2019-09-05 |
| DRIVEN: Accelerating Medical Entrepreneurship in the Northeast · topic 500 | Celdara Medical, LLC · New Hampshire | Department of Health and Human Services · National Institutes of Health | STTR Phase II | $3.17M | 2019-09-01 |
| Cellular Immunotherapy for Systemic Sclerosis · topic NIAMS | Celdara Medical, LLC · New Hampshire | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $1.48M | 2019-09-01 |
| Mitigation of Acute Kidney Injury (AKI) using the polymer prodrug, APP-103TM · topic 400 | Celdara Medical, LLC · New Hampshire | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $224.2K | 2019-05-01 |
| A novel antibody therapy for Sin Nombre virus infection · topic NIAID | Celdara Medical, LLC · New Hampshire | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $594.3K | 2019-01-01 |
| Discovery of Parasite-Derived Tolerogenic Adjuvants · topic NIAID | Celdara Medical, LLC · New Hampshire | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $599.2K | 2019 |
| Complex 3-Dimensional in vitro Human Skin Tissue Models for Scleroderma · topic NIAMS | Celdara Medical, LLC · New Hampshire | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $1.49M | 2018-09-14 |
| Specificity and safety of a targeted therapy against triple negative breast cancer · topic 102 | Celdara Medical, LLC · New Hampshire | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $300.0K | 2018-08-09 |
| Development of CM-SV1, a monoclonal antibody treatment for Sudan Virus · topic NIAID | Celdara Medical, LLC · New Hampshire | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $595.1K | 2018-02-16 |
| Discovery of novel helminth immunomodulatory proteins for autoimmune diseases · topic NIAID | Celdara Medical, LLC · New Hampshire | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $598.0K | 2018 |
| Cellular Immunotherapy for SSc · topic NIAMS | Celdara Medical, LLC · New Hampshire | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $225.0K | 2017-09-07 |
| Complex Dimensional in Vitro Human Skin Tissue Models for Scleroderma · topic NIAMS | Celdara Medical, LLC · New Hampshire | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $225.0K | 2017-09-07 |
| Therapeutic antibodies for treatment of hantavirus cardiopulmonary syndrome · topic R | Celdara Medical, LLC · New Hampshire | Department of Health and Human Services · National Institutes of Health | STTR Phase I | $800.1K | 2017-08-08 |
| Development of GIFT4: a B cell focused immunotherapy for cancer · topic NCI | Celdara Medical, LLC · New Hampshire | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $2.00M | 2017-05-12 |
| Preclinical development of inhalable glutaredoxin-1 for the treatment of IPF · topic NHLBI | Celdara Medical, LLC · New Hampshire | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $1.50M | 2017-02-01 |
| Therapy of transplantation-induced oxidative injury using polymeric antioxidants · topic 400 | Celdara Medical, LLC · New Hampshire | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $1.48M | 2015-08-01 |
| Preclinical development of inhalable glutaredoxin-1 for the treatment of IPF · topic NHLBI | Celdara Medical, LLC · New Hampshire | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $224.9K | 2015-08-01 |
| Preclinical Development of BILT, a Next-Generation Immunotoxin Therapy for CTCL · topic 102 | Celdara Medical, LLC · New Hampshire | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $299.1K | 2015-05-01 |
| IGF OT IGF MULTIPLEXED BIOMARKER ASSAY FOR CLASSIFICATION OF PATIENTS WITH SYSTEMIC SCLEROSIS · topic NIDA | Celdara Medical, LLC · New Hampshire | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $1.50M | 2015 |
| Gene Expression Signatures to Predict Treatment Response in Systemic Sclerosis · topic NIAMS | Celdara Medical, LLC · New Hampshire | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $1.49M | 2014-09-23 |
| Destroying the HIV-1 provirus by utilizing components of the CRISPR/Cas system · topic NIAID | Celdara Medical, LLC · New Hampshire | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $451.6K | 2014 |
Source: SBIR.gov award data (SBA) ↗, awards through 2026-08-28. Amounts are as agencies report them to SBA. SBIR/STTR contracts also appear in USAspending as ordinary awards; grants (NIH, NSF, DOE) appear as assistance. Open topics are posted by each agency; see Opportunities for contract notices.